Edwards Lifesciences
838 hedge funds and large institutions have $25.5B invested in Edwards Lifesciences in 2018 Q2 according to their latest regulatory filings, with 82 funds opening new positions, 286 increasing their positions, 314 reducing their positions, and 54 closing their positions.
52% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 54
11% more call options, than puts
Call options by funds: $152M | Put options by funds: $136M
5% more funds holding in top 10
Funds holding in top 10: 21 → 22 (+1)
3% more funds holding
Funds holding: 815 → 838 (+23)
5% more capital invested
Capital invested by funds: $24.3B → $25.5B (+$1.16B)
0.55% more ownership
Funds ownership: 249.42% → 249.97% (+0.55%)
9% less repeat investments, than reductions
Existing positions increased: 286 | Existing positions reduced: 314
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$233M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$187M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$109M |
| 4 |
WCM Investment Management
Laguna Beach,
California
|
+$63.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$88.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$80.6M |
| 3 |
Renaissance Technologies
New York
|
-$71.7M |
| 4 |
Two Sigma Advisers
New York
|
-$71.7M |
| 5 |
Bank of New York Mellon
New York
|
-$70.9M |
EW Hedge Fund Activity: Q2 2018 in Review
838 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2018, worth a combined $25.5B — up 4.8% from $24.3B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new EW positions and 54 closed out — a net gain of 28 holders — while 286 added to existing stakes and 314 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $233M. The largest seller was Goldman Sachs, cutting an estimated $88.9M.
- 838 institutional investors held Edwards Lifesciences (EW) as of Q2 2018, up from 815 in Q1 2018.
- Funds reported $25.5B of Edwards Lifesciences stock for Q2 2018, up 4.8% quarter-over-quarter.
- 82 funds opened new Edwards Lifesciences positions in Q2 2018 and 54 closed out, a net change of +28 holders.
- The largest Edwards Lifesciences buyer in Q2 2018 was Fidelity Investments, an estimated $233M added.
- The largest Edwards Lifesciences seller in Q2 2018 was Goldman Sachs, an estimated $88.9M sold.
Based on aggregated 13F filings for Q2 2018.